Groundbreaking tests to address unmet needs

TriVerity white

Uniquely designed to inform patient infection and illness severity status

  • severity icon redHow sick is the patient?
  • TriVerity determines infection typeAre the patient’s symptoms likely due to an infection, and what type?

The TriVerity Test is designed to complement how physicians evaluate patients suspected of acute infections and sepsis.

Inflammatix analysis
screen results

Sample test result screen showing high likelihood of a severe viral infection

The TriVerity Test (in development) measures the expression levels of 29 genes in blood, many of them related to the innate immune response. The test then combines expression levels using machine learning derived algorithms to generate three clinically actionable results in approximately 30 minutes1:
  • bacteria icon greyDoes the patient have a bacterial infection?
  • virus icon greyDoes the patient have a viral infection?
  • severity icon greyDoes the patient need ICU-level care?*

*Defined as the need for mechanical ventilation, vasopressors, and/or renal replacement therapy (RRT) within seven days.

Our products are in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.

TriVerity is being designed to help emergency medicine physicians make better decisions, particularly in situations where the patient status is unclear regarding important questions like:

  • red prescribeShould antibiotics be prescribed?
  • red assessAre additional tests necessary?
  • red admitWhat level of care is needed?
TriVerity can help make better decisions

Contact us to engage in research collaboration opportunities.

The TriVerity Test System, including the TriVerity Cartridge and Myrna Instrument, is designed to be easy to use and fit within routine clinical and laboratory workflows. System features include:
  • RWhole blood collected via routine phlebotomy
  • RNo sample manipulation (no pipetting or transfer)
  • RLess than one minute operator time to start a test
  • RTriVerity Test results in approximately 30 minutes
  • RSimple cleaning
  • RNo on-instrument reagents
  • RTriVerity Cartridges stored at room temperature
  • RSmall footprint benchtop analyzer
  • RStackable instruments for higher volume settings

Easy to use

Myrna stacked instruments

Myrna Instruments are easily configurable in a 2×2 format.

TriVerity Classifiers have been developed using thousands of patient samples across dozens of studies promising reliable performance and generalizability

endotypes logo

We think the precision medicine playbook that has worked in cancer can work in sepsis

Considering that not a single immunomodulatory therapy for sepsis has been successfully brought to market despite 40+ years of trials,2 a novel approach is needed.

A modern understanding of sepsis suggests that the sepsis syndrome may actually be composed of several subtypes of patients. Similar to how breast cancer is now properly defined as composed of different subtypes (e.g., ER/PR/HER2 status), a sepsis patient may someday be properly defined as suffering from overramped innate immunity, adaptive immune collapse, endothelial dysfunction, etc. And just like different breast cancer survival rates have improved as each subtype guides a specific treatment, so may sepsis outcomes improve when specific therapies are paired with individual subtypes.3 Our products are in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.

Endotypes helps differentiate patients

Our Endotypes program is at the forefront in sepsis therapy selection research

Inflammatix has been at the forefront of sepsis subtypes (or ‘endotypes’) research in transcriptomics, with a classifier that has been validated4,5 in research settings to produce subgroups with different outcomes. We are actively working to determine which therapies may show a difference in treatment effects among them.

Inflammatix collaborates with others committed to applying precision medicine in sepsis

drug and device development

Drug & Device Development

Inflammatix is working with drug and device companies to help identify patients likely to respond to novel and existing therapies. Interested parties can contact us at
bd [at]
SUBSPACE consortium

SUBSPACE Consortium

(SUBtyping in SePsis And Critical illnEss)

Inflammatix is also currently sponsoring the SUBSPACE Consortium, a collaborative of leading researchers and clinicians comparing different existing subtype classifiers.
To learn more please visit the SUBSPACE Consortium at

Clinical trials enrolling

Seeking Clinical Trialists

Inflammatix has several clinical studies in progress. Clinical trialists interested in validating Inflammatix endotypes should contact clinical [at]

Looking for other ways to collaborate?

Our pipeline of novel and rapid tests

the Inflammatix pipeline
  1. He, Y.D., et al., The Optimization and Biological Significance of a 29-Host-Immune-mRNA Panel for the Diagnosis of Acute Infections and Sepsis. J. Pers. Med. 2021, 11, 735.
  2. Opal S.M., et al., The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*. Crit Care Med. 2014 Jul;42(7):1714-21.
  3. Maslove D.M., et al., Redefining critical illness. Nat Med 28, 1141–1148 (2022).
  4. Iglesias J., et al., A 33-mRNA Classifier Is Able to Produce Inflammopathic, Adaptive, and Coagulopathic Endotypes with Prognostic Significance: The Outcomes of Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in the Early Treatment of Sepsis (ORANGES) Trial. J. Pers. Med. 2021; 11(1):9.
  5. Sweeney T.E., et al., Validation of Inflammopathic, Adaptive, and Coagulopathic Sepsis Endotypes in Coronavirus Disease 2019. Crit Care Med: February 2021 – Volume 49 – Issue 2 – p e170-e178.1; 51:e13626.